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Muscle Relaxants-Decamethonium
In 1948 two papers appeared in the journal Nature on the curare-like properties of polymethylene bisquaternary ammonium salts. Barlow and Ing in Oxford and Paton and Zaimis in London had separately reached the conclusion that these compounds had neuromuscular blocking properties. Their work had centred around bisquaternary compounds with varying methylene chains; neuromuscular blocking properties were found in those with ten groups (C10) and those with fi ve (C5) were shown to be autonomic ganglion blockers.
Following animal experiments, Paton and Zaimis, from the National Institute for Medical Research, and Geoffrey Organe, an anaesthetist at Westminster Hospital, decided to conduct clinical trials of C10 on humans, using themselves as the 'volunteers'. They conducted the experiments on fi ve occasions. Cyril Scurr was the Senior Anaesthetic Registrar at the Westminster and was given the job of administering the drug and, if necessary, resuscitating the volunteers-not an enviable task when your superior is on the operating table and the drug is completely untested. Given the level of responsibility he assumed, it seems unfair that his name did not appear on the paper that resulted from these experiments.
The experiments, conducted in a disused theatre, went well. "It had a pleasant view from the seventh fl oor over St John's Gardens, and we were equipped with an operating table and full anaesthetic apparatus." Each person was given 3 mg of decamethonium (C10) and each noticed paralysis of the eyes and eyelids within 20 seconds. The peak of the paralysis occurred within four minutes and by this time, all had developed immobility of their limbs and head, a reduction in abdominal tone and diminished hand strength. They had impaired speech but were able to cough and their vital capacity was diminished by about 35%. They reported that there were no important side-effects seen: "There was a rise of pulserate and blood-pressure, synchronous with the development of the paralysis, which began to pass off in 5 or 6 min. (probably this was of emotional origin)." They did notice something unusual. "During the beginning of the paralysis a vague feeling of slight tightness of the muscles was noted subjectively for a brief time and then passed off." Later it was realized that this was due to depolarization, something which had not been seen with muscle relaxants before.
It soon became apparent that this drug was different from curare and its synthetic alternatives. Stanley Feldman relates a story that a pigeon fl ew into Zaimis' laboratory and was subjected to an experimental dose of decamethonium. Traditionally the bird headdrop test had been used to standardize samples of Intocostrin and she expected the pigeon's head to fall. The bird's neck extended violently as the neck muscles went into spasm. Birds soon had another role in the testing of muscle relaxants as this test became the standard indicator of this depolarizing block.
There were other differences. Unexpectedly it was found that neostigmine did not reverse the action of decamethonium. Pentamethonium (C5) did reverse its actions and Paton and his colleagues tested this effect during their preliminary testing. They all experienced faster recovery from the relaxant with C5 but also developed severe hypotension if they tried to stand: one actually fainted. It was soon apparent that this side-effect made it an inappropriate drug for reversal of decamethonium, but that it did have application as a hypotensive agent to decrease blood loss in certain situations.
Following the preliminary trials of decamethonium, clinical trials were conducted by Organe. Before the trials were completed, the drug was released on to the market and an interim report was produced. Decamethonium ('Eulissin', 'Syncurine') was marketed as a solution containing 2 mg/ml. It seems extraordinary that it was released within months of the fi rst experiments on humans.
By this time Organe and his colleagues had used decamethonium for 150 cases, mostly laparotomies. They found it to be a safe and effective substitute for curare although slightly shorter-acting, requiring further doses between ten and forty minutes apart. They found it unnecessary to use pentamethonium for reversal. They had no signifi cant complications and also found it to be satisfactory for caesarean section. Maureen Young at St Thomas's Hospital conducted trials specifi cally on caesarean section patients and felt that decamethonium had a defi nite advantage over curare: "Repeated or large doses of C10 do not depress the arterial blood pressure, and this seems to be a very important reason for substituting C10 for d-tubocurarine chloride whenever possible."
The following year Cyril Scurr published a series of peroral endoscopy patients who had received decamethonium. Curare was too long-acting for these procedures: "… one authority has described its use for this purpose as a steam-hammer blow" so a shorter-acting drug was highly sought after. Decamethonium was used in this instance to provide relaxation of the jaw and to prevent laryngeal spasm; a full relaxant dose was not used. The patients were given oxygen for the fi rst three to four minutes until relaxation was maximal: "This is an important point, as apnoea, should it occur, is well tolerated in the presence of full oxygenation of the lungs." It was also pointed out that it was the duty of the anaesthetist to maintain adequate oxygenation should apnoea occur: "Adequate respiratory exchange should be ensured by gentle compression of the fl anks and lower ribs (as in Schäfer's method) or, in the intubated cases, by rhythmic pressure on the rebreathing bag of the anaesthetic apparatus."
Further experience with decamethonium showed that repeated doses led to tachyphylaxis and increasing doses were required. This led to problems with recovery, as there was no suitable antidote. Later it was discovered that neostigmine was able to partially reverse these particular cases although the reason for this was unclear. It was still hoped that a shorter-acting drug would become available. As suxamethonium was already under investigation, its release on to the market soon led to a decrease in the use of decamethonium.
